Andre H Crepaldi

Brazilian Real-World Multiple Myeloma (MM) Electronic Platform Register Project

Emanuel Silva, Rafael Dezen Gaiolla, João Tadeu Damian Souto Filho, 2020 .

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

Andre H Crepaldi, M. Dimopoulos, A. Jakubowiak, 2017, The New England journal of medicine.

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone

Andre H Crepaldi, M. Dimopoulos, A. Jakubowiak, 2019, Blood.

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

Andre H Crepaldi, M. Dimopoulos, A. Jakubowiak, 2019, The Lancet.

Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial

Andre H Crepaldi, M. Dimopoulos, A. Jakubowiak, 2021, BMC cancer.

Characteristics of follicular and mantle cell lymphoma in Brazil: prognostic impact of clinical parameters and treatment conditions in two hospitals

Andre H Crepaldi, F. Soares, M. Delamain, 2018, Hematology, transfusion and cell therapy.

Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study

Andre H Crepaldi, M. Dimopoulos, A. Jakubowiak, 2022, Blood.

Pre-analytical parameters associated with unsuccessful karyotyping in myeloid neoplasm: a study of 421 samples

Andre H Crepaldi, P. Campregher, N. Hamerschlak, 2019, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.